{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:39:56Z","timestamp":1770565196091,"version":"3.49.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/wnf.0b013e31815a3f03","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T21:27:58Z","timestamp":1236288478000},"page":"189-196","source":"Crossref","is-referenced-by-count":38,"title":["Caffeine and Progression of Parkinson Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"David K.","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Swearingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Aminoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara C.","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9","key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.55.9.1350","article-title":"Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.","volume":"55","author":"Benedetti","year":"2000","journal-title":"Neurology"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","article-title":"Association of coffee and caffeine intake with the risk of Parkinson disease.","volume":"283","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2003.07.006","article-title":"Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese.","volume":"216","author":"Tan","year":"2003","journal-title":"J Neurol Sci"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","article-title":"Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann Neurol"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp.2005.065417","article-title":"Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease.","volume":"77","author":"Evans","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.","volume":"105","author":"Xu","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","article-title":"Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.","volume":"22","author":"Hauser","year":"2005","journal-title":"Drugs Aging"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A(2A) receptor antagonist is tradefylline in advanced PD.","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.","volume":"68","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.20361","article-title":"A responsive outcome for Parkinson's disease neuroprotection futility studies.","volume":"57","author":"Elm","year":"2005","journal-title":"Ann Neurol"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jama.1991.03470010097038","article-title":"Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.","volume":"266","author":"Yusuf","year":"1991","journal-title":"JAMA"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol Rev"},{"issue":"8","key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.58.8.1154","article-title":"Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.","volume":"58","author":"Schwarzschild","year":"2002","journal-title":"Neurology"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/japplphysiol.00255.2001","article-title":"Opposite actions of caffeine and creatine on muscle relaxation time in humans.","volume":"92","author":"Hespel","year":"2002","journal-title":"J Appl Physiol"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1152\/jappl.1996.80.2.452","article-title":"Caffeine counteracts the ergogenic action of muscle creatine loading.","volume":"80","author":"Vandenberghe","year":"1996","journal-title":"J Appl Physiol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200807000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:35:46Z","timestamp":1738978546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200807000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31815a3f03","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}